Clinical Trial Update: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of a fixed-dose combination of ledipasvir/sofosbuvir for 12 weeks in patients with chronic genotype 1 or 4 hepa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Drugs mentioned

• Ledipasvir/Sofosbuvir fixed-dose combination (Ledipasvir + Sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus, HIV | Phase 3 | Status: COMPLETED | Results posted: 2016-10-21